Navigation Links
The Results From a Clinical Trial Led by the Montreal Heart Institute Demonstrate That Drug Reduces Inflammation in Patients With Serious Cardiovascular Disease
Date:11/10/2008

MONTREAL, Nov. 10 /PRNewswire/ -- Montreal Heart Institute Research Centre Director Dr. Jean-Claude Tardif presented yesterday results from a clinical trial demonstrating that VIA-2291, an investigational drug being developed by VIA Pharmaceuticals, Inc., significantly inhibited production of leukotrienes, proposed mediators of vascular inflammation, in patients with serious heart disease. VIA-2291 was well-tolerated with no serious adverse events attributed to the drug. The study was presented in a Special Session at the American Heart Association 2008 Scientific Sessions in New Orleans, Louisiana.

The study of VIA-2291 was designed to establish optimal dosing and safety data in patients with acute coronary syndromes (ACS), who recently had a heart attack or unstable angina. 191 patients were treated once daily for 12 weeks with one of three dose levels of VIA-2291 or placebo. A sub-study of patients continued for an additional 12 weeks of treatment.

Cardiologists have several therapies that help reduce heart disease risk factors, but none that specifically target inflammation, an underlying cause of atherosclerosis, which leads to major adverse cardiac events (MACE), including heart attack and stroke.

VIA-2291 is designed to be a selective and reversible inhibitor of 5-LO, a key enzyme in the biosynthesis of leukotrienes, that are important mediators of inflammation believed to be involved in the development and progression of atherosclerosis.

"VIA-2291 has the potential to be the first drug to specifically target one cardiovascular inflammatory pathway," said Dr. Jean-Claude Tardif, the VIA-2291 ACS trial's principal investigator, director of the Montreal Heart Institute Research Centre and professor of medicine at the Universite de Montreal. "These data support further clinical development of this drug, including larger outcome trials."

Study Results

The trial demonstrated a statistically significant, dose-depende
'/>"/>

SOURCE Montreal Heart Institute
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3

Related medicine news :

1. Chindex International Inc. Reports Second Quarter FY 2009 Financial Results
2. Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance
3. MGT Capital Investments Reports Third Quarter 2008 Financial Results and Provides Update on Recent Developments
4. China Sky One Medical, Inc. Announces Record Third Quarter 2008 Results
5. Ellex Announces Six-Month Results on Retina Regeneration Therapy
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
7. InfoLogix to Report Third Quarter Financial Results on November 10, 2008
8. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
9. China Pharma Holdings, Inc. Reports Third Quarter 2008 Financial Results and Corporate Updates
10. Fraxel(R) Laser Systems Shown to Provide Superior Results Compared to Pseudo Fractional Laser Technologies
11. NutraCea Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Today, Zane Benefits, Inc. published a ... Benefits, which provides comprehensive and flexible alternatives to traditional ... defined contribution plans and health reimbursement arrangements ... from employees is “does my employer have to provide ... The health care reform law, called the Affordable Care ...
(Date:5/23/2013)... Denise Mann HealthDay Reporter , , THURSDAY, May ... Americans take to help treat hip and knee osteoarthritis ... risk for developing glaucoma, a small new study of ... is an increase of intraocular pressure (IOP) or pressure ... the leading causes of blindness. In ...
(Date:5/23/2013)... a year ago, the leading journal Science ... drug. A significant breakthrough and an important starting point ... De Strooper Alzheimer,s researcher at VIB and KU ... D,Hooge KU Leuven and scientists at Janssen ... Alzheimer,s animal test models. Their results were different, as ...
(Date:5/23/2013)... An anti-cancer drug about to be tested in ... as a possible treatment for Alzheimer,s disease has failed ... that plague Alzheimer,s patients, according to results of a ... Ph.D., a professor of neuroscience affiliated with the Evelyn ... University of Florida, emphasized the importance of verifying promising ...
(Date:5/23/2013)... May 23, 2013 Dr. Katherine Ahn ... charitable organization in Orange County, OCCares , will hold ... County. The event details are as follows: , Sunday ... Auditorium, 13732 Clinton Street, Garden Grove, CA 92843 , The ... music by Christian vocalists Charmaine & Jonathan Thulin. There ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on the Employer Mandate 2Health News:Zane Benefits Publishes New Information on the Employer Mandate 3Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3Health News:New insights contradict promising Alzheimer's research 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3
... National American Heart Month, PITTSBURGH, Feb. 14 ... to grow its outreach efforts with new and ... Children,s Hospital,are increasing access to state-of-the-art pediatric cardiac ... and more., By providing expanded and new ...
... tips to relieve stress, a common cause of heart ... ... makes us think,of love and Valentine,s Day. This February, which also is National ... organ, your heart. A healthy heart can be attained in a variety,of ways ...
... Dental Professionals Kick off Year-Long Initiative, PLAINVIEW, N.Y., ... world is about to become brighter. That,s the number ... at the first of,Davis Vision,s 2008 free vision screening ... attracted 100 children,ages 5 through 16 from all over ...
... metabolite disrupts hormone-sensitive cells, study finds , , THURSDAY, Feb. ... finally explain how a key compound found in the ... tumors. , The new report, published in the open ... DDT,s main metabolite blocks a pathway of a hormone ...
... One of the Nation,s Leading Amateur Teen Golfers - MacKinzie Kline - Hosts, Event to ... , WHO: Fifteen-year old amateur golfer and CHF national ... born with a congenital heart ... Golf Event benefitting the Children,s Heart Foundation. ...
... how flexing muscles tell nearby blood vessels that they ... published Feb. 15 in the journal Circulation Research. The ... involve poor circulation like peripheral artery disease, which comes ... amputation in the worst cases. Furthermore, the same signals ...
Cached Medicine News:Health News:Children's Hospital Heart Center Continues to Expand Outreach Efforts to Increase Access to Quality Care for More Families 2Health News:Children's Hospital Heart Center Continues to Expand Outreach Efforts to Increase Access to Quality Care for More Families 3Health News:Healthy Heart, Healthy Home 2Health News:Davis Vision, United Concordia Free Clinic Promotes Children's Eye and Dental Health 2Health News:Davis Vision, United Concordia Free Clinic Promotes Children's Eye and Dental Health 3Health News:DDT Compound Speeds Breast Cancer Growth 2Health News:Children's Heart Foundation (CHF) Hosts 4th Annual Arizona 'Swing For Their Hearts' Golf Event 2Health News:Researchers discover new way to reverse poor circulation and heal wounds 2Health News:Researchers discover new way to reverse poor circulation and heal wounds 3Health News:Researchers discover new way to reverse poor circulation and heal wounds 4
(Date:5/23/2013)... , May 23, 2013 Israel ... Israel 2013 , Israel,s 1 st ... October 14 th -15 th in Tel ... most innovative city in the world by the Wall ... BrainTech Israel 2013 will showcase the latest breakthroughs ...
(Date:5/23/2013)... , May 23, 2013 EarlySense, ... today that the prize for ,Best Novel Idea, at ... Medical Emergency Teams International Conference, hosted this year in ... awarded to a clinical research team studying the impact ... Hospital in Los Angeles . The ...
(Date:5/23/2013)... 2013 SynCardia Systems, Inc. ( www.syncardia.com ), ... Canada and CE ( Europe ) approved ... Centre in Scotland , which boasts ... SynCardia temporary Total Artificial Heart powered by the ... Bodyworks Exhibition, one of the most advanced exhibitions of ...
Breaking Medicine Technology:Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 2Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 3Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 4Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3
... 6, 2011 Fuisz Pharma LLC announced today a ... swallowing and esophageal transit. Clinical studies ... esophageal transit by 80%, ease the swallowing experience, and ... with the conventional tablet designs currently used. ...
... 2011 Michigan,s providers of home-based care are asking ... "competitive" bidding program for home medical equipment and services. ... later this year in three metropolitan areas in the ... will affect many of Michigan,s 1.6 million Medicare beneficiaries. ...
Cached Medicine Technology:Fuisz Pharma LLC Develops a New Generation of Oral Solid Dosage Form Shapes That Facilitate Swallowing and Esophageal Transit 2Michigan Home Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 2Michigan Home Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 3Michigan Home Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 4
The IDS Gamma-B 25-Hydroxy Vitamin D kit is a conventional liquid phase radioimmunoassay intended for the quantitative determination of 25-hydroxy vitamin D (25-OHD) and other hydroxylated metabolite...
... Pro is a portable, easy-to-use device ... parameters PT, APTT, and ACT. It ... hospitals and medical offices for hematology ... catheterization laboratories, and dialysis centers for ...
Tenderlett finger incision devices are designed to fit the contour of the finger. Tenderlett is available in three different incision depths from toddler to adult and color-code for easy identificat...
The Unistik 3 family of single use safety lancets has 4 models for use across all clinical environments....
Medicine Products: